Drug firms hype disease as sales ploy, industry chief claimsBMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7342.867 (Published 13 April 2002) Cite this as: BMJ 2002;324:867
- Ray Moynihan
A senior pharmaceutical company executive says estimates of the prevalence of diseases are often exaggerated.
Using the example of his company's promotion of “social phobia,” Fred Nadjarian, managing director of Roche in Australia, said: “The marketing people always beat [hype] these things up. It's just natural enthusiasm.”
The candid comments come as the pharmaceutical industry intensifies its push to loosen European regulations on direct-to-consumer promotions involving both “disease awareness campaigns” and straight advertisements for …
Log in using your username and password
Log in through your institution
Sign up for a free trial